MAHAVIR ADVANCED REMEDIES LIMITED

(Formerly known as : Indo-American Advanced Pharmaceuticals Ltd.)

Regd. Office : No. 91, D-11, Govindappa Naicken Street, Chennai 600 001
CIN - L24231TN1992PLC022562, Email : indoamerican1234@gmail.com, Wesbite : www.iaap.in
Rs. in Lacs
Statement of Unaudited Financial Results for the Quarter ended 30th June 2014

Particulars
Sr.
No.
1 Income from Operations

3 Months
ended
30.06.2014

Preceding 3
Months ended
31.03.2014

Corresponding 3
Months ended
30.06.2013

Year to date
figures as on
31.03.2014

Un-Audited

Audited*

Un-Audited

Audited

a) Net Sales/Income/(Loss) from Investing Activities

2.42

b) Other Operating Income

Total Income from Operations (Net)
2

2.50

10.29

2.42

2.39

2.50

10.29

Expenses
(a) Cost of Material Consumed

(b) Purchases of Stock-in-trade

Trade

(d) Employees Benefit Expenses

0.36

5.70

0.30

(e) Depreciation & Amortization Expenses

(f) Loss on Sale of Fixed Assets

6.60
-

(g) Other Expenses

1.24

9.51

1.04

11.63

Total Expenses

1.60

15.21

1.34

18.23

0.82
-

(12.83)
21.72

1.16
-

(7.95)
21.72

0.82
-

8.89
-

1.16
-

13.77
-

0.82
-

8.89
(4.07)

1.16
-

13.77
-

Profit/(Loss) from Operations before other Income, finance cost and

exceptional Expenses (1-2)

Other Income/(Loss)

Profit/(Loss) from ordinary activities before finance costs and exceptional

items (3+4)

Finance Costs

Profit/(Loss) from ordinary activities after finance cost but before

exceptional items (3+4)

Exceptional Items

Profit(+)/Loss(-) from ordinary activites before Tax (7-8)

10 Tax Expenses
11 Net Profit (+)/Loss(-) from ordinary activites after tax (9-10)
12 Extra Ordinary Items (Net of Tax Expense of Rs.
13 Net Profit (+)/Loss(-) for the period (11-12)

Lac)

14 Share of Profit/(Loss) of Associates*

15 Minority Interest*
Net Profit (+)/Loss(-) after tax, minority interest and Share of Profit / (Loss)
16 of Associates (13-14-15)
17 Paid-up Equity Share Capital (Face Value of Rs. 10/- each)
18 Reserves excluding revaluation Reserves as per last Balance Sheet

0.82
-

12.96
-

1.16
0.30

13.77
-

0.82
-

12.96
-

0.86
-

13.77
-

0.82
-

12.96
-

0.86
-

13.77
-

0.82
1,135.92

12.96
1,135.92

0.86
1,135.92

13.77
1,135.92

0.01
0.01

0.11
0.11

0.01
0.01

0.12
0.12

0.01
0.01

0.11
0.11

0.01
0.01

0.12
0.12

11,249,550

11,249,550

10,438,800

11,249,550

99.03

99.03

91.90

99.03

a) Pledged/Encumbered

- Number of Shares

- Percentage of Shares (as a % of the total Shareholding

Earning Per Share (before extra-ordinary items) of Rs. 10/- each (not
19 annualized)
(i) a) Basic
b) Diluted
Earning Per Share (after extra-ordinary items) of Rs. 10/- each (not
19 annualized)
(ii) a) Basic
b) Diluted
A

2.39

PARTICULARS OF SHAREHOLDING
Public Shareholding
- Number of Shares
- Percentage of Share Holding

(256.74)

18 Promoter and Promoter Group Shareholding

of Promoter and Promoter Group

- Percentage of Shares (as a % of the total Share Capital of the Company
b) None-Encumbered
- Number of Shares
- Percentage of Shares (as a % of the total Shareholding

109,650

109,650

920,400

109,650

100.00

100.00

100.00

100.00

0.97

0.97

8.10

0.97

of Promoter and Promoter Group

- Percentage of Shares (as a % of the total Share Capital of the Company
B

INVESTOR COMPLAINTS
Pending at the beginning of the Quarter

Nil

Received during the Quarter

Disposed during the Quarter

Remaining Unresolved at the end of Quarter

Nil

Notes :
1. Segmental Report for the Quarter as per AS-17 of ICAI is not applicable for the Quarter.
2. Above resultes were reviewed by Audit Committee taken on record in Board Meeting held on 12th August, 2014.
*3. The figures of preceding Quarter ended 31st March 2014 are the balancing figures between Audited figures in respect of full financial year
and the published year to date figures upto the 3rd Quarter of the Previous Financial Year.
4. The Statutory Auditors of the Company have carried out "Limited Review" of the above Financial Results.

Place : Chennai
Date : 12th August, 2014.

For MAHAVIR ADVANCED REMEDIES LIMITED

S/dB.V.S. KOTESWARA RAO
Managing Director